Work

Figure S1,Table S1 from Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

Year: 2023

Type: other

Abstract: Supplementary figure S1: IL-10, IL-1RA and Eotaxin plasma concentration in patients pre- vs. post-treatment with Cetuximab plus motolimod. Supplementary table S1: 95% confidence interval for figure 5 comparing pre vs post treatment expression changes of TIGIT, PD-1, CTLA-4 and CD27.

DOI: 10.1158/1078-0432.22462056.v1

Authors: Gulidanna Shayan, Benjamin A. Kansy, Sandra P. Gibson, Raghvendra M. Srivastava, James Kyle Bryan, Julie E. Bauman, James Ohr, Seungwon Kim, Umamaheswar Duvvuri, David A. Clump, Dwight E. Heron, Jonas T. Johnson, Robert M. Hershberg, Robert L. Ferris

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361920448

Cites:

Cited by:

Related to: 10